{{Rsnum
|rsid=6951651
|Gene=RELN
|Chromosome=7
|position=103903456
|Orientation=plus
|GMAF=0.4697
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=RELN
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 10.6 | 51.3 | 38.1
| HCB | 57.4 | 37.5 | 5.1
| JPT | 60.2 | 33.6 | 6.2
| YRI | 31.7 | 47.6 | 20.7
| ASW | 19.3 | 66.7 | 14.0
| CHB | 57.4 | 37.5 | 5.1
| CHD | 59.6 | 35.8 | 4.6
| GIH | 32.7 | 46.5 | 20.8
| LWK | 33.6 | 46.4 | 20.0
| MEX | 19.6 | 53.6 | 26.8
| MKK | 26.9 | 51.9 | 21.2
| TSI | 11.8 | 48.0 | 40.2
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6951651
|Name_s=
|Gene_s=RELN
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.41, combined P value= 2.30E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470213
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6951651
|overall_frequency_n=73
|overall_frequency_d=126
|overall_frequency=0.579365
|n_genomes=43
|n_genomes_annotated=0
|n_haplomes=62
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}